rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Avita Medical, Inc.

RCEL · Nasdaq

Health CareMedical DevicesLeading

RCEL stood above a rising 150-day average in 17 of the last 52 weekly readings, including each of the last 17 weeks. It is 127.4% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
17 in a row
Industry in uptrend
29% -4 in 4 wk
Insider buys, 12 months
$469K
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
70 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

22 Apr – 21 Oct
15%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$379KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 0, Senate 0, executive 1; 1 people.

WhoDidAmountTraded
Keith Sonderling Executive branch: Office of Government EthicsDepartment of Laborsold$1k–$15k28 Mar 2025filed 14 May 2025

Insiders

Buy orders, 12 months10
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
David D. O'TooleCFObought2,000at $3.9712 Jun 2026filed 24 Aug 2026
Joseph Fralin WoodyDirectorbought5,000at $4.209 Jun 2026filed 9 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.189 Jun 2026filed 9 Jun 2026
Joseph Fralin WoodyDirectorbought5,200at $4.009 Jun 2026filed 10 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.103 Jun 2026filed 5 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.093 Jun 2026filed 5 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.182 Jun 2026filed 3 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.212 Jun 2026filed 3 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.341 Jun 2026filed 3 Jun 2026
Joseph Fralin WoodyDirectorbought5,000at $4.261 Jun 2026filed 3 Jun 2026
David D. O'TooleCFObought2,000at $4.2620 May 2026filed 20 May 2026
David D. O'TooleCFObought2,000at $4.2419 May 2026filed 19 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders70-3 on the quarter
New · exited20 · 25
Reported value$20.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,333,914$5.5M-1,238−0.1%
BlackRock, Inc.reduced · filed 7 Aug 2026564,952$2.3M-568,174−50.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026339,822$1.4M-203,152−37.4%
MARSHALL WACE, LLPadded · filed 13 Aug 2026338,387$1.4M+285,825+543.8%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026321,013$1.3M+226,652+240.2%
MORGAN STANLEYadded · filed 13 Aug 2026200,462$828K+42,841+27.2%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026182,402$753K-11,034−5.7%
NewEdge Advisors, LLCnew · filed 12 Aug 2026148,931$615K+148,931
MACQUARIE GROUP LTDadded · filed 14 Aug 2026144,164$595K+132,262+1111.3%
STATE STREET CORPreduced · filed 7 Aug 2026128,977$533K-300,045−69.9%
31 Mar 2023 – 30 Jun 2026
606773Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David D. O'Toole Company insiderCFO · last 12 Jun 202622 · 0
Joseph Fralin Woody Company insiderDirector · last 9 Jun 20265 · 0
Cary Guy Vance Company insiderPresident and CEO · last 29 May 20260 · 0
Nicole Kelsey Company insiderChief Legal Officer · last 18 Feb 20260 · 0
Jan Stern Reed Company insiderDirector · last 20 Jan 20260 · 0
Jeremy Curnock Cook Company insiderDirector · last 20 Jan 20260 · 2
Michael E. Tarnoff Company insiderDirector · last 20 Jan 20260 · 0
Robert McNamara Company insiderDirector · last 20 Jan 20264 · 0
Suzanne Crowe Company insiderDirector · last 20 Jan 20262 · 0
Keith Sonderling Executive branchDepartment of Labor · last 28 Mar 20250 · 1
James Corbett Company insiderCEO · last 21 Jan 20250 · 1
Lou Panaccio Company insiderDirector · last 21 Jan 20250 · 0

Same industry

HTFL HeartflowLeading+59%
ATRC AtriCureLeading+51%
HAE HaemoneticsLeading+44%
BVS BioventusLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202582.1%
Operating profit marginFY 2025 · to 31 Dec 2025-59.4%
Free cash flow marginFY 2025 · to 31 Dec 2025-45.0%
Interest coverFY 2025 · to 31 Dec 2025-8.50×
Research spendFY 2025 · to 31 Dec 202529.1%
Share count trendFY 2025 · to 6 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$10.2M
Free cash flowFY 2025 · to 31 Dec 2025−$32.2M

Analyst forecasts

No analyst forecasts yet.